Xencor Company Profile (NASDAQ:XNCR)

About Xencor (NASDAQ:XNCR)

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XNCR
  • CUSIP: N/A
  • Web: www.xencor.com/
Capitalization:
  • Market Cap: $1.07 billion
  • Outstanding Shares: 46,703,000
Average Prices:
  • 50 Day Moving Avg: $21.71
  • 200 Day Moving Avg: $23.23
  • 52 Week Range: $18.10 - $29.38
P/E:
  • Trailing P/E Ratio: 66.91
  • Foreward P/E Ratio: -16.20
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $84.61 million
  • Price / Sales: 12.70
  • Book Value: $6.51 per share
  • Price / Book: 3.53
Profitability:
  • EBIDTA: $15.7 million
  • Net Margins: -337.21%
  • Return on Equity: -19.01%
  • Return on Assets: -13.86%
Debt:
  • Current Ratio: 1.55%
  • Quick Ratio: 1.55%
Misc:
  • Average Volume: 242,392 shs.
  • Beta: 2.13
  • Short Ratio: 8.3
 

Frequently Asked Questions for Xencor (NASDAQ:XNCR)

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.06. The company had revenue of $4.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 337.21% and a negative return on equity of 19.01%. View Xencor's Earnings History.

When will Xencor make its next earnings announcement?

Xencor is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Xencor.

Where is Xencor's stock going? Where will Xencor's stock price be in 2017?

6 brokerages have issued twelve-month price targets for Xencor's shares. Their predictions range from $21.00 to $35.00. On average, they expect Xencor's share price to reach $28.60 in the next year. View Analyst Ratings for Xencor.

What are analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (4/29/2017)
  • 2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)

Who are some of Xencor's key competitors?

Who are Xencor's key executives?

Xencor's management team includes the folowing people:

  • Bruce L.A. Carter Ph.D., Independent Chairman of the Board
  • Bassil I. Dahiyat Ph.D., President, Chief Executive Officer, Founder, Director
  • John R. Desjarlais Ph.D., Senior Vice President, Research and Chief Scientific Officer
  • Paul Foster M.D., Senior Vice President, Chief Medical Officer
  • John J. Kuch, Vice President - Finance
  • Edgardo Baracchini Jr. Ph.D., Chief Business Officer
  • A. Bruce Montgomery M.D., Lead Independent Director
  • Robert F. Baltera Jr., Independent Director
  • Kevin C. Gorman Ph.D., Independent Director
  • Kurt A. Gustafson, Independent Director

Who owns Xencor stock?

Xencor's stock is owned by a number of of institutional and retail investors. Top institutional investors include Creative Planning (0.08%) and Equitec Specialists LLC (0.01%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Who sold Xencor stock? Who is selling Xencor stock?

Xencor's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Xencor stock in the last year include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais and John S Stafford III. View Insider Buying and Selling for Xencor.

Who bought Xencor stock? Who is buying Xencor stock?

Xencor's stock was bought by a variety of institutional investors in the last quarter, including Equitec Specialists LLC. View Insider Buying and Selling for Xencor.

How do I buy Xencor stock?

Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of Xencor stock can currently be purchased for approximately $23.00.


MarketBeat Community Rating for Xencor (NASDAQ XNCR)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  212
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Xencor (NASDAQ:XNCR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $28.60 (24.35% upside)

Analysts' Ratings History for Xencor (NASDAQ:XNCR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017WedbushReiterated RatingOutperform$29.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$21.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
11/28/2016Canaccord GenuitySet Price TargetBuy$32.00N/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$26.00N/AView Rating Details
10/4/2016Piper Jaffray CompaniesInitiated CoverageOverweight$35.00N/AView Rating Details
5/2/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00N/AView Rating Details
8/5/2015MLV & Co.Reiterated RatingBuy$22.00 -> $29.00N/AView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Xencor (NASDAQ:XNCR)
Earnings by Quarter for Xencor (NASDAQ:XNCR)
Earnings History by Quarter for Xencor (NASDAQ XNCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017($0.28)N/AView Earnings Details
5/9/2017Q1 2017($0.25)($0.31)$8.15 million$4.34 millionViewListenView Earnings Details
8/2/2016Q216($0.18)$1.13$7.43 million$66.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details
5/4/2015Q115($0.17)($0.19)$1.90 million$1.49 millionViewListenView Earnings Details
2/19/2015($0.22)($0.04)$1.33 million$5.66 millionViewN/AView Earnings Details
11/10/2014Q3 14($0.19)($0.20)$1.50 million$0.85 millionViewN/AView Earnings Details
7/31/2014($0.19)($0.16)$0.82 millionViewN/AView Earnings Details
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xencor (NASDAQ:XNCR)
2017 EPS Consensus Estimate: ($0.92)
2018 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.17)($0.20)
Q2 20172($0.29)($0.19)($0.24)
Q3 20172($0.32)($0.20)($0.26)
Q4 20172($0.24)($0.21)($0.23)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.41)($0.41)($0.41)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Xencor (NASDAQ:XNCR)
Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 75.00%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/28/2017John S Stafford IIIMajor ShareholderBuy6,000$19.94$119,640.00View SEC Filing  
6/16/2017John S Stafford IIIMajor ShareholderBuy1,500$19.67$29,505.00View SEC Filing  
6/14/2017Bruce L A CarterDirectorSell20,000$20.61$412,200.00View SEC Filing  
6/2/2017Bruce L A CarterDirectorSell2,366$22.00$52,052.00View SEC Filing  
5/26/2017Bruce L A CarterDirectorSell12,400$22.19$275,156.00View SEC Filing  
5/2/2017Edgardo Baracchini JrInsiderSell10,568$26.01$274,873.68View SEC Filing  
4/27/2017Edgardo Baracchini JrInsiderSell904$26.04$23,540.16View SEC Filing  
3/16/2017John J. KuchVPSell15,000$24.42$366,300.00View SEC Filing  
3/8/2017Edgardo Baracchini JrInsiderSell1,821$25.00$45,525.00View SEC Filing  
12/6/2016John S Stafford IIIMajor ShareholderSell63,061$27.71$1,747,420.31View SEC Filing  
9/28/2016Edgardo Baracchini JrInsiderSell10,000$25.35$253,500.00View SEC Filing  
9/27/2016John S Stafford IIIMajor ShareholderSell40,000$25.72$1,028,800.00View SEC Filing  
9/2/2016Edgardo Baracchini JrInsiderSell10,000$21.06$210,600.00View SEC Filing  
8/30/2016Bassil I DahiyatInsiderSell40,000$21.80$872,000.00View SEC Filing  
8/26/2016John S Stafford IIIMajor ShareholderSell24,351$21.48$523,059.48View SEC Filing  
8/24/2016John J KuchVPSell25,000$21.95$548,750.00View SEC Filing  
8/23/2016John R DesjarlaisVPSell16,294$21.73$354,068.62View SEC Filing  
8/23/2016John S Stafford IIIMajor ShareholderSell96,828$21.73$2,104,072.44View SEC Filing  
8/16/2016Bassil I DahiyatInsiderSell45,886$22.06$1,012,245.16View SEC Filing  
8/15/2016Bruce L A CarterDirectorSell3,400$22.67$77,078.00View SEC Filing  
8/15/2016John S Stafford IIIMajor ShareholderSell10,000$23.06$230,600.00View SEC Filing  
8/11/2016John S Stafford IIIMajor ShareholderSell30,500$21.87$667,035.00View SEC Filing  
8/10/2016Edgardo Baracchini JrInsiderSell2,500$21.83$54,575.00View SEC Filing  
8/3/2016Edgardo Baracchini, Jr.InsiderSell4,528$20.00$90,560.00View SEC Filing  
8/3/2016John R. DesjarlaisVPSell5,905$20.00$118,100.00View SEC Filing  
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.50View SEC Filing  
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.00View SEC Filing  
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00View SEC Filing  
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.00View SEC Filing  
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72View SEC Filing  
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.60View SEC Filing  
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.75View SEC Filing  
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.75View SEC Filing  
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.00View SEC Filing  
12/17/2015John J KuchVPSell4,781$14.89$71,189.09View SEC Filing  
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.25View SEC Filing  
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.00View SEC Filing  
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.00View SEC Filing  
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Xencor (NASDAQ:XNCR)
Latest Headlines for Xencor (NASDAQ:XNCR)
Source:
DateHeadline
americanbankingnews.com logoZacks: Analysts Expect Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - July 20 at 6:24 PM
finance.yahoo.com logoXencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : July 6, 2017
finance.yahoo.com - July 6 at 3:26 PM
americanbankingnews.com logoXencor, Inc. (XNCR) Major Shareholder John S. Stafford III Acquires 6,000 Shares
www.americanbankingnews.com - June 30 at 7:29 PM
americanbankingnews.com logoXencor, Inc. (XNCR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 30 at 11:05 AM
americanbankingnews.com logoXencor, Inc. (XNCR) Expected to Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - June 28 at 11:10 AM
americanbankingnews.com logo-$0.25 EPS Expected for Xencor, Inc. (XNCR) This Quarter
www.americanbankingnews.com - June 26 at 4:12 PM
americanbankingnews.com logoXencor, Inc. (XNCR) Major Shareholder Purchases $29,505.00 in Stock
www.americanbankingnews.com - June 20 at 7:50 PM
rttnews.com logoFDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG's R2 Regimen
www.rttnews.com - June 19 at 8:06 AM
nasdaq.com logoFDA Nod For Ipsen, XNCR On Watch, Results MAGINIFY CELG's R2 Regimen
www.nasdaq.com - June 18 at 7:58 PM
streetinsider.com logoXencor (XNCR) Reports Interim Data from an Ongoing Open-Label Phase 2 Study of XmAb5871 in IgG4-Related Disease
www.streetinsider.com - June 18 at 12:10 AM
finance.yahoo.com logoXencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017
finance.yahoo.com - June 17 at 7:49 AM
americanbankingnews.com logoInsider Selling: Xencor, Inc. (XNCR) Director Sells 20,000 Shares of Stock
www.americanbankingnews.com - June 16 at 7:34 PM
americanbankingnews.com logoXencor's (XNCR) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - June 16 at 4:22 PM
finance.yahoo.com logoETFs with exposure to Xencor, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 8:15 PM
finance.yahoo.com logoXencor, Inc. :XNCR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 10 at 3:41 AM
finance.yahoo.com logoXencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology
finance.yahoo.com - June 9 at 2:48 AM
americanbankingnews.com logoBruce L. A. Carter Sells 2,366 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - June 6 at 8:40 PM
americanbankingnews.com logoXencor Inc (XNCR) Given Outperform Rating at Wedbush
www.americanbankingnews.com - June 6 at 4:20 PM
americanbankingnews.com logoXencor Inc (XNCR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 5 at 11:10 AM
americanbankingnews.com logo Analysts Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - June 2 at 1:48 PM
americanbankingnews.com logoBruce L. A. Carter Sells 12,400 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - May 31 at 10:26 PM
americanbankingnews.com logo-$0.25 Earnings Per Share Expected for Xencor Inc (XNCR) This Quarter
www.americanbankingnews.com - May 31 at 10:26 AM
finance.yahoo.com logoXencor to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 8:06 AM
finance.yahoo.com logoWorst-Performing Gurus' Stocks
finance.yahoo.com - May 24 at 8:04 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Xencor Inc Lowered by Analyst (XNCR)
www.americanbankingnews.com - May 12 at 7:50 AM
americanbankingnews.com logoXencor Inc (XNCR) to Post Q2 2017 Earnings of ($0.29) Per Share, Wedbush Forecasts
www.americanbankingnews.com - May 12 at 7:50 AM
streetinsider.com logoXencor (XNCR) Announces Orphan Drug Designation from FDA for XmAb5871 to Treat IgG4-Related Disease
www.streetinsider.com - May 11 at 3:20 PM
finance.yahoo.com logoXencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
finance.yahoo.com - May 11 at 3:20 PM
finance.yahoo.com logoEdited Transcript of XNCR earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:46 AM
americanbankingnews.com logoXencor Inc (XNCR) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 5:18 PM
finance.yahoo.com logoInvestor Network: Xencor, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 9:38 AM
americanbankingnews.com logoXencor Inc (XNCR) Rating Reiterated by Wedbush
www.americanbankingnews.com - May 10 at 9:18 AM
finance.yahoo.com logoXencor reports 1Q loss
finance.yahoo.com - May 9 at 8:16 PM
americanbankingnews.com logoXencor Inc (XNCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 9 at 10:31 AM
finance.yahoo.com logoXencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : May 9, 2017
finance.yahoo.com - May 9 at 9:29 AM
americanbankingnews.com logoXencor Inc (XNCR) Expected to Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - May 7 at 8:16 AM
americanbankingnews.com logoXencor Inc (XNCR) to Release Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:20 AM
americanbankingnews.com logo Analysts Anticipate Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - May 5 at 12:18 PM
americanbankingnews.com logoXencor (XNCR) Given Daily Media Sentiment Rating of 0.17
www.americanbankingnews.com - May 3 at 4:26 PM
americanbankingnews.com logoInsider Selling: Xencor Inc (XNCR) Insider Sells 10,568 Shares of Stock
www.americanbankingnews.com - May 2 at 9:54 PM
finance.yahoo.com logoXencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
finance.yahoo.com - May 2 at 8:08 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Unlikely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 30 at 8:45 AM
americanbankingnews.com logoXencor Inc (XNCR) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 29 at 7:26 AM
americanbankingnews.com logoXencor Inc (XNCR) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 7:10 AM
americanbankingnews.com logoInsider Selling: Xencor Inc (XNCR) Insider Sells 904 Shares of Stock
www.americanbankingnews.com - April 27 at 9:56 PM
americanbankingnews.com logoXencor (XNCR) Receives Media Impact Rating of 0.31
www.americanbankingnews.com - April 27 at 8:34 AM
finance.yahoo.com logoXencor, Inc. – Value Analysis (NASDAQ:XNCR) : April 26, 2017
finance.yahoo.com - April 26 at 5:22 PM
finance.yahoo.com logoXencor to Present at 42nd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 26 at 8:11 AM
finance.yahoo.com logoXencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : April 25, 2017
finance.yahoo.com - April 25 at 7:39 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 23 at 11:49 AM

Social

Chart

Xencor (XNCR) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff